Our Approach

Dr. Bell is co-founder of Myracle Therapeutics.  A 10 year veteran of Novartis, she delivered Entresto ($5B) approval 18 months ahead of schedule as global GM, securing Break-Through and Fast-Track status at the FDA.  She has developed and launched over a dozen innovative medicines and had roles of increasing responsibility on 9 cardiovascular outcomes trials. An early commercial leader at The Medicines Company (NASDAQ: MDCO), she contributed to market cap growth from $400M to >$2B within 3 years.   She earned her PharmD from the University of Florida, where she also completed a fellowship in cardiovascular pharmacogenomics. Before joining the industry, she spent 10 years at the bedside as a research clinical pharmacist.  She is a board director, start-up thought leader, and advisor for life-science companies, research institutes, CEOs, founders, and innovation accelerators in the US, Canada, and Europe.  She is CEO of Antilia Biosciences and currently serves on the board of New York Bio.

Dr. McKinsey is co-founder of Myracle Therapeutics and a Professor in the Department of Medicine/Division of Cardiology at the University of Colorado Anschutz Medical Campus in Denver, where he holds the Joseph and Rose LaConte Cardiology Endowed Chair. Dr. McKinsey is also Associate Division Head for Translational Research and Director of the university’s Consortium for Fibrosis Research & Translation (CFReT; www.cfret.org). He obtained a PhD from Vanderbilt University School of Medicine where he studied in the laboratory of Dr. Dean Ballard. Dr. McKinsey’s postdoctoral training was done in the laboratory of Dr. Eric Olson at the University of Texas Southwestern Medical Center in Dallas. The focus of his lab is to translate basic discoveries to novel therapies for patients with cardiometabolic diseases.